Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Change in Cash (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Change in Cash data on record, last reported at -$2.4 million in Q4 2025.

  • For Q4 2025, Change in Cash fell 9.83% year-over-year to -$2.4 million; the TTM value through Dec 2025 reached $3.5 million, up 157.81%, while the annual FY2025 figure was $4.5 million, 292.42% up from the prior year.
  • Change in Cash reached -$2.4 million in Q4 2025 per INM's latest filing, down from -$1.7 million in the prior quarter.
  • Across five years, Change in Cash topped out at $8.0 million in Q3 2021 and bottomed at -$5.4 million in Q1 2022.
  • Average Change in Cash over 5 years is -$22682.9, with a median of -$1.0 million recorded in 2024.
  • Peak YoY movement for Change in Cash: tumbled 348.26% in 2023, then soared 721.59% in 2025.
  • A 5-year view of Change in Cash shows it stood at -$4.1 million in 2021, then soared by 151.73% to $2.1 million in 2022, then soared by 33.04% to $2.8 million in 2023, then plummeted by 177.37% to -$2.2 million in 2024, then fell by 9.83% to -$2.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Cash were -$2.4 million in Q4 2025, -$1.7 million in Q3 2025, and $6.4 million in Q2 2025.